# A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

> **NCT00684632** · PHASE3 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 51 (actual)

## Conditions studied

- Pain, Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** KW-2246 (fentanyl citrate)

## Key facts

- **NCT ID:** NCT00684632
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684632, "A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00684632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*